Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Insurance Firm Humana Shares Fall After Q3 Performance - Here's Why

Published 01/11/2023, 16:23
Updated 01/11/2023, 17:40
© Reuters.  Insurance Firm Humana Shares Fall After Q3 Performance - Here's Why

Benzinga - by Vandana Singh, Benzinga Editor.

Humana Inc (NYSE: HUM) reported Q3 adjusted EPS of $7.78 compared to $7.31 a year ago, beating the consensus of $7.16.

The insurer reported revenue of $26.42 billion, up from $22.78 billion a year ago, missing the consensus of $25.55 billion.

Sales increased on individual Medicare Advantage and state-based contracts membership growth and higher per member individual Medicare Advantage premiums.

Humana's individual Medicare Advantage enrollment was 5.37 million at the end of the third quarter, up 17.8%. Total Medical Membership decreased slightly by 0.8% to 16.96 million.

In the third quarter, Humana's profits fell 30% to $830 million.

Humana reported a benefits expense ratio of 86.4% for the quarter, up from 85.3% a year earlier.

Citing Morningstar analyst Julie Utterback, Reuters noted that shares fell on disappointing that Humana did not increase its full-year guide despite a strong quarter.

The company's caution relates to elevated demand for non-urgent surgeries that has affected the insurance industry and may constrain Humana's Q4 results, Utterback added.

Guidance: Humana reaffirms adjusted EPS guidance of at least $28.25 versus the consensus Of $28.3.

Humana sees FY23 GAAP EPS of 'at least $26.31' from 'at least $26.91' prior.

Sees FY23 Insurance segment benefit expense ratio of around 87.5% versus 86.3%-87.3% expected earlier.

The company sees FY23 year-end medical membership Individual Medicare Advantage Growth of around 860,000 versus growth of approximately 825,000 expected earlier.

Price Action: HUM shares are down 3.91% at $503.21 on the last check Wednesday.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.